Log in
(Ad)
Located just 25 miles from Cleveland... is a supergreenhouse unlike anything we've ever seen. Listed at over 1.4 million sq ft, (the size of 9 full-sized Costco warehouses), this marijuana grow house is capable of producing over 341,000 pounds of weed/year! And very soon it will come online and could turn a tiny 60-cent pot company into the dominator in the white-hot weed market.

NASDAQ:KALA - Kala Pharmaceuticals Stock Price, Forecast & News

$6.52
+0.84 (+14.79 %)
(As of 01/20/2020 06:00 AM ET)
Today's Range
$5.52
Now: $6.52
$6.69
50-Day Range
$3.63
MA: $4.34
$6.52
52-Week Range
$3.24
Now: $6.52
$9.25
Volume1.22 million shs
Average Volume777,858 shs
Market Capitalization$225.20 million
P/E RatioN/A
Dividend YieldN/A
Beta2.16
Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KALA
CUSIPN/A
Phone781-996-5252

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.11 per share

Profitability

Net Income$-66,740,000.00

Miscellaneous

Employees130
Market Cap$225.20 million
Next Earnings Date3/9/2020 (Estimated)
OptionableOptionable

Receive KALA News and Ratings via Email

Sign-up to receive the latest news and ratings for KALA and its competitors with MarketBeat's FREE daily newsletter.


(Ad)


Official tax return reveals how one trader nabbed annual gains of 228%, 309% and 339%. His tax return was released online, exposing this simple trading technique used to pocket nearly half a million in profits.

Kala Pharmaceuticals (NASDAQ:KALA) Frequently Asked Questions

What is Kala Pharmaceuticals' stock symbol?

Kala Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALA."

How were Kala Pharmaceuticals' earnings last quarter?

Kala Pharmaceuticals Inc (NASDAQ:KALA) issued its quarterly earnings data on Thursday, November, 7th. The company reported ($0.68) EPS for the quarter, missing analysts' consensus estimates of ($0.67) by $0.01. The business had revenue of $1.45 million for the quarter, compared to analyst estimates of $3.56 million. View Kala Pharmaceuticals' Earnings History.

When is Kala Pharmaceuticals' next earnings date?

Kala Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Kala Pharmaceuticals.

What price target have analysts set for KALA?

5 analysts have issued 1 year price targets for Kala Pharmaceuticals' shares. Their forecasts range from $6.00 to $51.00. On average, they anticipate Kala Pharmaceuticals' stock price to reach $18.20 in the next year. This suggests a possible upside of 179.1% from the stock's current price. View Analyst Price Targets for Kala Pharmaceuticals.

What is the consensus analysts' recommendation for Kala Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kala Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kala Pharmaceuticals.

Has Kala Pharmaceuticals been receiving favorable news coverage?

News coverage about KALA stock has trended positive on Monday, InfoTrie reports. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Kala Pharmaceuticals earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Kala Pharmaceuticals.

Are investors shorting Kala Pharmaceuticals?

Kala Pharmaceuticals saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 4,700,000 shares, an increase of 14.1% from the December 15th total of 4,120,000 shares. Based on an average trading volume of 451,100 shares, the days-to-cover ratio is currently 10.4 days. Approximately 17.6% of the company's shares are short sold. View Kala Pharmaceuticals' Current Options Chain.

Who are some of Kala Pharmaceuticals' key competitors?

What other stocks do shareholders of Kala Pharmaceuticals own?

Who are Kala Pharmaceuticals' key executives?

Kala Pharmaceuticals' management team includes the folowing people:
  • Mr. Mark T. Iwicki, Chairman, Pres & CEO (Age 53)
  • Mr. Todd Bazemore, Chief Operating Officer (Age 49)
  • Dr. Kim Brazzell, Chief Medical Officer (Age 66)
  • Dr. Justin Hanes Ph.D., Founder & Chair of the Scientific Advisory Board
  • Ms. Mary Reumuth CPA, CPA, CFO & Treasurer (Age 44)

When did Kala Pharmaceuticals IPO?

(KALA) raised $90 million in an initial public offering (IPO) on Thursday, July 20th 2017. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers.

Who are Kala Pharmaceuticals' major shareholders?

Kala Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Wedbush Securities Inc. (0.45%). Company insiders that own Kala Pharmaceuticals stock include Gregory Grunberg, Howard B Rosen, Orbimed Advisors Llc and Ra Capital Healthcare Fund Lp. View Institutional Ownership Trends for Kala Pharmaceuticals.

Which institutional investors are buying Kala Pharmaceuticals stock?

KALA stock was purchased by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. Company insiders that have bought Kala Pharmaceuticals stock in the last two years include Gregory Grunberg, Howard B Rosen, Orbimed Advisors Llc and Ra Capital Healthcare Fund Lp. View Insider Buying and Selling for Kala Pharmaceuticals.

How do I buy shares of Kala Pharmaceuticals?

Shares of KALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Kala Pharmaceuticals' stock price today?

One share of KALA stock can currently be purchased for approximately $6.52.

How big of a company is Kala Pharmaceuticals?

Kala Pharmaceuticals has a market capitalization of $225.20 million. The company earns $-66,740,000.00 in net income (profit) each year or ($2.48) on an earnings per share basis. Kala Pharmaceuticals employs 130 workers across the globe.View Additional Information About Kala Pharmaceuticals.

What is Kala Pharmaceuticals' official website?

The official website for Kala Pharmaceuticals is http://www.kalarx.com/.

How can I contact Kala Pharmaceuticals?

Kala Pharmaceuticals' mailing address is 490 ARSENAL WAY SUITE 120, WALTHAM MA, 02453. The company can be reached via phone at 781-996-5252 or via email at [email protected]


MarketBeat Community Rating for Kala Pharmaceuticals (NASDAQ KALA)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  224 (Vote Outperform)
Underperform Votes:  225 (Vote Underperform)
Total Votes:  449
MarketBeat's community ratings are surveys of what our community members think about Kala Pharmaceuticals and other stocks. Vote "Outperform" if you believe KALA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KALA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel